Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring minimal residual disease in AML: the right time for real time.

Annals of hematology - 1 Mar 2003

Jaeger U, Kainz B

Abstract excerpt

Detection of minimal residual disease (MRD) by polymerase chain reaction (PCR) has become an essential tool for molecular monitoring of acute myeloid leukemia (AML). Currently, specific translocation markers are available for 40-50% of AMLs. Expression markers may widen this spectrum to 70-90%. Quantitative PCR (Q-PCR, real-time PCR) is now as sensitive as conventional two-step PCR and could improve as well as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Duplication
Share to Genetic Markers
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm, Residual

Share to Prognosis

Share to Recurrence

Share to Sensitivity and Specificity

Share to Translocation, Genetic

Source

Identifiers

PMID: 12634945
DOI: 10.1007/s00277-002-0601-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring minimal residual disease in AML: the right time for real time.PMID 12634945Read ↗

Monitoring of minimal residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Detection of minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.Semantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaSemantic proximity Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Tumor heterogeneity makes AML a "moving target" for detection of residual disease.Semantic proximity Read ↗

Detection and management of minimal residual disease in acute lymphoblastic leukemiaSemantic proximity Read ↗

Minimal residual disease in acute myeloid leukemia: coming of age.Semantic proximity Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.